Patents by Inventor Hiroshi Nara

Hiroshi Nara has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210040989
    Abstract: A sintered bearing is made of a sintered compact containing nickel silver (Cu—Ni—Zn) as a base. In the sintered bearing, P is not added in the sintered compact. Alternatively, a content of P in the sintered compact is less than 0.05 mass % in terms of mass ratio to a total mass. Consequently, crystal grains constituting the sintered compact can be micronized. In particular, in the sintered bearing, an average crystal particle diameter of the crystal grains constituting the sintered compact is 20 ?m or less. Consequently, the mechanical strength and the vibration resisting properties can be improved, and the rotation shaft can be prevented from being damaged.
    Type: Application
    Filed: January 25, 2019
    Publication date: February 11, 2021
    Inventors: Shigeyuki TANABE, Shinobu ASO, Hiroshi NARA
  • Publication number: 20210024512
    Abstract: The present invention provides a heterocyclic compound having an activity to promote the maturation of a cardiomyocyte. A compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof has an activity to promote the maturation of a cardiomyocyte, and is useful as a cardiomyocyte maturation promoter.
    Type: Application
    Filed: March 28, 2019
    Publication date: January 28, 2021
    Applicants: Kyoto University, Takeda Pharmaceutical Company Limited
    Inventors: Yoshinori YOSHIDA, Kenji MIKI, Akira KAIEDA, Shigeru KONDO, Hiroshi NARA, Yoshinori IKEURA
  • Publication number: 20200388354
    Abstract: An objective of the present invention is to provide a document creation assistance server and document creation assistance method which are capable of efficiently acquiring information necessary to write a specification or other such documents, and of generating a document from the acquired information.
    Type: Application
    Filed: September 10, 2018
    Publication date: December 10, 2020
    Inventors: Hiroshi NARA, Junya SHIRAI, Tatsuki KOIKE, Kenjiro SATO, Takaharu HIRAYAMA, Hiromi FUKUDA, Tsutomu MORITA, Hiromasa ISHIHARA, Kazue SUZUKI, Hiroki SAKAMOTO, Fumiaki KIKUCHI, Kenta TAMAKI, Toru TANOUE, Yuichi HORITA, Takeshi UEDA
  • Publication number: 20200163970
    Abstract: Provided is a novel compound or salt thereof that induces degradation by autophagy of an intracellular molecule. In this compound, a ligand having activity to bind to an intracellular molecule and a structure having activity to induce autophagy of an intracellular molecule are linked via a linker without loss of the activity of the ligand and the structure.
    Type: Application
    Filed: February 2, 2018
    Publication date: May 28, 2020
    Inventors: Hirokazu ARIMOTO, Kaori ITTO, Daiki TAKAHASHI, Nobuo CHO, Hiroshi NARA, Kenichiro SHIMOKAWA, Taiichi OHRA, Shigekazu SASAKI, Naoki ISHII
  • Patent number: 10406146
    Abstract: The present invention provides a heterocyclic compound having a HDAC inhibitory action, and useful for the treatment of inflammatory disease and the like, and a medicament comprising the compound. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.
    Type: Grant
    Filed: August 24, 2016
    Date of Patent: September 10, 2019
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Akira Kaieda, Naoki Ishii, Hiroshi Nara, Masato Yoshikawa, Masaki Daini
  • Patent number: 10357484
    Abstract: The present invention provide a heterocyclic compound having a HDAC inhibitory action, and useful for the treatment of autoimmune diseases and/or inflammatory diseases, graft versus host disease, cancers, central nervous diseases including neurodegenerative diseases, Charcot-Marie-Tooth disease and the like, and a medicament comprising the compound. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.
    Type: Grant
    Filed: July 15, 2016
    Date of Patent: July 23, 2019
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Akira Kaieda, Masaki Daini, Hiroshi Nara, Masato Yoshikawa, Naoki Ishii, Masashi Toyofuku, Kousuke Hidaka
  • Patent number: 10308643
    Abstract: The present invention provide a heterocyclic compound having a HDAC inhibitory action, and useful for the treatment of autoimmune diseases and/or inflammatory diseases, graft versus host disease, cancers, central nervous diseases including neurodegenerative diseases, Charcot-Marie-Tooth disease and the like, and a pharmaceutical composition comprising the compound. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.
    Type: Grant
    Filed: July 15, 2016
    Date of Patent: June 4, 2019
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Akira Kaieda, Masashi Toyofuku, Masaki Daini, Hiroshi Nara, Masato Yoshikawa, Naoki Ishii, Kousuke Hidaka
  • Publication number: 20190008836
    Abstract: The present invention provide a heterocyclic compound having a HDAC inhibitory action, and useful for the treatment of autoimmune diseases and/or inflammatory diseases, graft versus host disease, cancers, central nervous diseases including neurodegenerative diseases, Charcot-Marie-Tooth disease and the like, and a medicament comprising the compound. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.
    Type: Application
    Filed: July 15, 2016
    Publication date: January 10, 2019
    Inventors: Akira KAIEDA, Masaki DAINI, Hiroshi NARA, Masato YOSHIKAWA, Naoki ISHII, Masashi TOYOFUKU, Kousuke HIDAKA
  • Patent number: 10081624
    Abstract: The present invention provides a heterocyclic compound having a HDAC inhibitory action, and useful for the treatment of autoimmune diseases and/or inflammatory diseases, graft versus host disease, cancers, central nervous diseases including neurodegenerative diseases and the like, and a medicament comprising the compound. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.
    Type: Grant
    Filed: August 25, 2015
    Date of Patent: September 25, 2018
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Akira Kaieda, Naoki Ishii, Hiroshi Nara, Masato Yoshikawa, Masaki Daini, Masashi Toyofuku, Kousuke Hidaka
  • Publication number: 20180263967
    Abstract: The present invention provides a heterocyclic compound having a HDAC inhibitory action, and useful for the treatment of inflammatory disease and the like, and a medicament comprising the compound. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.
    Type: Application
    Filed: August 24, 2016
    Publication date: September 20, 2018
    Inventors: Akira KAIEDA, Naoki ISHII, Hiroshi NARA, Masato YOSHIKAWA, Masaki DAINI
  • Publication number: 20180222896
    Abstract: The present invention provides a heterocyclic compound having a HDAC inhibitory action, and useful for the treatment of autoimmune diseases and/or inflammatory diseases, graft versus host disease, cancers, central nervous diseases including neurodegenerative diseases and the like, and a medicament comprising the compound. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.
    Type: Application
    Filed: August 25, 2015
    Publication date: August 9, 2018
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Akira Kaieda, Noaki Ishii, Hiroshi Nara, Masato Yoshikawa, Masaki Daini, Mashashi Toyofuku, Kousuke Hidaka
  • Patent number: 10038882
    Abstract: A projector and a method of controlling the projector that may give information on suitability of a light source. A projector includes light sources, light modulators (liquid crystal panels) that modulate lights output from the light sources, a projection optical device that projects the lights modulated by the light modulators, a determination unit that determines whether or not a light source unadapted to a mounting position of the projector is attached, and an informing unit (display control unit) that, if a determination that the light source unadapted to the mounting position of the projector is attached is made by the determination unit, gives information in response to a determination result.
    Type: Grant
    Filed: February 27, 2015
    Date of Patent: July 31, 2018
    Assignee: SEIKO EPSON CORPORATION
    Inventors: Takanori Fukuyama, Hiroshi Nara, Kazunori Maeta, Kaname Nagatani
  • Publication number: 20180118708
    Abstract: The present invention provides compounds having a Toll-like receptor 4 (TLR4) signaling inhibitory action useful as preventive and therapeutic drugs of autoimmune disease and/or inflammatory disease or diseases such as chemotherapy-induced peripheral neuropathy (CIPN), chemotherapy-induced neuropathic pain (CINP), liver injury, ischemia-reperfusion injury (IRI) and the like. The present invention relates to a compound represented by formula (I) and a salt thereof: (wherein, each symbol is explained in greater detail in the specification).
    Type: Application
    Filed: May 6, 2016
    Publication date: May 3, 2018
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Toshitake KOBAYASHI, Morihisa SAITOH, Yasufumi WADA, Hiroshi NARA, Nobuyuki NEGORO, Masashi YAMASAKI, Takahiro TANAKA, Naomi KITAMOTO
  • Patent number: 9828357
    Abstract: The present invention provides compounds having a Toll-like receptor 4 (TLR4) signaling inhibitory action useful as preventive and therapeutic drugs of inflammatory disease and/or central nervous system disease or diseases such as chemotherapy-induced peripheral neuropathy (CIPN), chemotherapy-induced neuropathic pain (CINP), liver injury, ischemia-reperfusion injury (IRI) and the like. The present invention relates to a compound represented by formula (I) and a salt thereof: wherein, each symbol is explained in greater detail in the specification.
    Type: Grant
    Filed: November 21, 2016
    Date of Patent: November 28, 2017
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Toshitake Kobayashi, Morihisa Saitoh, Yasufumi Wada, Hiroshi Nara, Nobuyuki Negoro, Taisuke Katoh, Masashi Yamasaki, Takahiro Tanaka, Naomi Kitamoto
  • Patent number: 9611244
    Abstract: The present invention provides compounds having a Toll-like receptor 4 (TLR4) signaling inhibitory action useful as preventive and therapeutic drugs of inflammatory disease and/or central nervous system disease or diseases such as chemotherapy-induced peripheral neuropathy (CIPN), chemotherapy-induced neuropathic pain (CINP), liver injury, ischemia-reperfusion injury (IRI) and the like. The present invention relates to a compound represented by formula (I) and a salt thereof: (wherein, each symbol is explained in greater detail in the specification).
    Type: Grant
    Filed: May 6, 2016
    Date of Patent: April 4, 2017
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Toshitake Kobayashi, Morihisa Saitoh, Yasufumi Wada, Hiroshi Nara, Nobuyuki Negoro
  • Publication number: 20170066737
    Abstract: The present invention provides compounds having a Toll-like receptor 4 (TLR4) signaling inhibitory action useful as preventive and therapeutic drugs of inflammatory disease and/or central nervous system disease or diseases such as chemotherapy-induced peripheral neuropathy (CIPN), chemotherapy-induced neuropathic pain (CINP), liver injury, ischemia-reperfusion injury (IRI) and the like. The present invention relates to a compound represented by formula (I) and a salt thereof: wherein, each symbol is explained in greater detail in the specification.
    Type: Application
    Filed: November 21, 2016
    Publication date: March 9, 2017
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Toshitake Kobayashi, Morihisa SAITOH, Yasufumi WADA, Hiroshi NARA, Nobuyuki NEGORO, Taisuke KATOH, Masashi YAMASAKI, Takahiro TANAKA, Naomi KITAMOTO
  • Publication number: 20170019649
    Abstract: A projector and a method of controlling the projector that may give information on suitability of a light source. A projector includes light sources, light modulators (liquid crystal panels) that modulate lights output from the light sources, a projection optical device that projects the lights modulated by the light modulators, a determination unit that determines whether or not a light source unadapted to a mounting position of the projector is attached, and an informing unit (display control unit) that, if a determination that the light source unadapted to the mounting position of the projector is attached is made by the determination unit, gives information in response to a determination result.
    Type: Application
    Filed: February 27, 2015
    Publication date: January 19, 2017
    Applicant: SEIKO EPSON CORPORATION
    Inventors: Takanori FUKUYAMA, Hiroshi NARA, Kazunori MAETA, Kaname NAGATANI
  • Publication number: 20170015655
    Abstract: The present invention provide a heterocyclic compound having a HDAC inhibitory action, and useful for the treatment of autoimmune diseases and/or inflammatory diseases, graft versus host disease, cancers, central nervous diseases including neurodegenerative diseases, Charcot-Marie-Tooth disease and the like, and a pharmaceutical composition comprising the compound. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.
    Type: Application
    Filed: July 15, 2016
    Publication date: January 19, 2017
    Inventors: Akira KAIEDA, Masashi TOYOFUKU, Masaki DAINI, Hiroshi NARA, Masato YOSHIKAWA, Naoki ISHII, Kousuke HIDAKA
  • Patent number: 9533966
    Abstract: The present invention provides compounds having a Toll-like receptor 4 (TLR4) signaling inhibitory action useful as preventive and therapeutic drugs of inflammatory disease and/or central nervous system disease or diseases such as chemotherapy-induced peripheral neuropathy (CIPN), chemotherapy-induced neuropathic pain (CINP), liver injury, ischemia-reperfusion injury (IRI) and the like. The present invention relates to a compound represented by formula (I) and a salt thereof: (wherein, each symbol is explained in greater detail in the specification).
    Type: Grant
    Filed: June 7, 2016
    Date of Patent: January 3, 2017
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Toshitake Kobayashi, Morihisa Saitoh, Yasufumi Wada, Hiroshi Nara, Nobuyuki Negoro
  • Publication number: 20160326102
    Abstract: The present invention provides compounds having a Toll-like receptor 4 (TLR4) signaling inhibitory action useful as preventive and therapeutic drugs of inflammatory disease and/or central nervous system disease or diseases such as chemotherapy-induced peripheral neuropathy (CIPN), chemotherapy-induced neuropathic pain (CINP), liver injury, ischemia-reperfusion injury (IRI) and the like. The present invention relates to a compound represented by formula (I) and a salt thereof: (wherein, each symbol is explained in greater detail in the specification).
    Type: Application
    Filed: May 6, 2016
    Publication date: November 10, 2016
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Toshitake Kobayashi, Morihisa SAITOH, Yasufumi WADA, Hiroshi NARA, Nobuyuki NEGORO, Taisuke KATOH, Masashi YAMASAKI, Takahiro TANAKA, Naomi KITAMOTO